Fig. 1

UNC5A is an estradiol (E2)-inducible gene. a Estrogen receptor (ER)α binding sites on UNC5A genomic region. Chromatin immunoprecipitation (ChIP)-seq datasets in MCF7 cells from Welboren et al. [27] (ER_minus ligand, ER-E2, ER-tamoxifen) and ChIP-on-chip datasets in MCF7 and MCF7 cells overexpressing constitutively active AKT from Bhat-Nakshatri et al. [9] were used to identify ERα binding sites on UNC5A genomic regions. Four ERα binding sites on chromosome 5 (hg18/human) are indicated on the top with genomic coordinates 176,169,194–176,169,471, 176,173,985–176,174,876, 176,206,209–176,206,749 and 176,229,374–176,230,036, respectively. b The effect of E2 (10⁻¹⁰ M), tamoxifen (OHT; 1 μM), or both on UNC5A expression in MCF7 cells. Cells were treated for 3 h and UNC5A levels were measured by qRT-PCR. Bar graphs represent mean ± SEM of fold change relative to vehicle control (n = 3). c ChIP assay confirms binding of ERα to UNC5A regulatory regions (second ERα binding site from the left). MCF7 cells were treated with vehicle or E2 (10⁻⁸ M) for 45 min and 2 h. ERα DNA binding levels are presented as mean ± SEM of non-normalized values relative to the vehicle sh-Control (n = 2). d mRNA levels of ESR1 and UNC5A show positive correlation in breast cancer cell lines. R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl) tool was used to obtain these results. e UNC5A mRNA levels in different subtypes of breast cancers in the TCGA dataset. Data were obtained using the public database UALCAN [28]. f NTN1 mRNA levels in different subtypes of breast cancers in the TCGA dataset. TNBC, triple negative breast cancer